Is the Affinity Column-Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?

M. K. Ju, H. K. Chang, H. J. Kim, K. H. Huh, H. J. Ahn, M. S. Kim, S. I. Kim, Y. S. Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Tacrolimus is a potent immunosuppressive drug used in organ transplantation. Because of its substantial toxic effects, narrow therapeutic index, and interindividual pharmacokinetic variability, therapeutic drug monitoring of whole-blood tacrolimus concentrations has been recommended. We investigated the comparability of the results of 2 immunoassay systems, affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA), comparing differences in the tacrolimus concentrations measured by the 2 methods in relation to the hematologic and biochemical values of hepatic and renal functions. Methods: A total of 154 samples from kidney or liver transplant recipients were subjected to Dimension RxL HM with a tacrolimus Flex reagent cartilage for the ACMIA method and IMx tacrolimus II for the MEIA method. Results: Tacrolimus concentrations measured by the ACMIA method (n = 154) closely correlated with those measured by the MEIA method (r = 0.84). The Bland-Altman plot using concentration differences between the 2 methods and the average of the 2 methods showed no specific trends. The tacrolimus levels determined by both the MEIA method and the ACMIA method were not influenced by hematocrit levels, but the difference between the 2 methods (ACMIA - MEIA) tended to be larger in low hematocrit samples (P < .001). Conclusion: The ACMIA method used for a tacrolimus assay is precise and has advantages, including the lack of a required pretreatment procedure. Furthermore, it is only slightly influenced by the hematologic or biochemical status of the samples.

Original languageEnglish
Pages (from-to)3673-3678
Number of pages6
JournalTransplantation Proceedings
Volume40
Issue number10
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Tacrolimus
Immunoenzyme Techniques
Immunoassay
Hematocrit
Kidney
Drug Monitoring
Poisons
Liver
Organ Transplantation
Therapeutic Uses
Immunosuppressive Agents
Cartilage
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

Ju, M. K. ; Chang, H. K. ; Kim, H. J. ; Huh, K. H. ; Ahn, H. J. ; Kim, M. S. ; Kim, S. I. ; Kim, Y. S. / Is the Affinity Column-Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?. In: Transplantation Proceedings. 2008 ; Vol. 40, No. 10. pp. 3673-3678.
@article{174c5ffc2ade44c4bf7c363b0ff90088,
title = "Is the Affinity Column-Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?",
abstract = "Background: Tacrolimus is a potent immunosuppressive drug used in organ transplantation. Because of its substantial toxic effects, narrow therapeutic index, and interindividual pharmacokinetic variability, therapeutic drug monitoring of whole-blood tacrolimus concentrations has been recommended. We investigated the comparability of the results of 2 immunoassay systems, affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA), comparing differences in the tacrolimus concentrations measured by the 2 methods in relation to the hematologic and biochemical values of hepatic and renal functions. Methods: A total of 154 samples from kidney or liver transplant recipients were subjected to Dimension RxL HM with a tacrolimus Flex reagent cartilage for the ACMIA method and IMx tacrolimus II for the MEIA method. Results: Tacrolimus concentrations measured by the ACMIA method (n = 154) closely correlated with those measured by the MEIA method (r = 0.84). The Bland-Altman plot using concentration differences between the 2 methods and the average of the 2 methods showed no specific trends. The tacrolimus levels determined by both the MEIA method and the ACMIA method were not influenced by hematocrit levels, but the difference between the 2 methods (ACMIA - MEIA) tended to be larger in low hematocrit samples (P < .001). Conclusion: The ACMIA method used for a tacrolimus assay is precise and has advantages, including the lack of a required pretreatment procedure. Furthermore, it is only slightly influenced by the hematologic or biochemical status of the samples.",
author = "Ju, {M. K.} and Chang, {H. K.} and Kim, {H. J.} and Huh, {K. H.} and Ahn, {H. J.} and Kim, {M. S.} and Kim, {S. I.} and Kim, {Y. S.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.transproceed.2008.04.019",
language = "English",
volume = "40",
pages = "3673--3678",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

Is the Affinity Column-Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay? / Ju, M. K.; Chang, H. K.; Kim, H. J.; Huh, K. H.; Ahn, H. J.; Kim, M. S.; Kim, S. I.; Kim, Y. S.

In: Transplantation Proceedings, Vol. 40, No. 10, 01.12.2008, p. 3673-3678.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is the Affinity Column-Mediated Immunoassay Method Suitable as an Alternative to the Microparticle Enzyme Immunoassay Method as a Blood Tacrolimus Assay?

AU - Ju, M. K.

AU - Chang, H. K.

AU - Kim, H. J.

AU - Huh, K. H.

AU - Ahn, H. J.

AU - Kim, M. S.

AU - Kim, S. I.

AU - Kim, Y. S.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: Tacrolimus is a potent immunosuppressive drug used in organ transplantation. Because of its substantial toxic effects, narrow therapeutic index, and interindividual pharmacokinetic variability, therapeutic drug monitoring of whole-blood tacrolimus concentrations has been recommended. We investigated the comparability of the results of 2 immunoassay systems, affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA), comparing differences in the tacrolimus concentrations measured by the 2 methods in relation to the hematologic and biochemical values of hepatic and renal functions. Methods: A total of 154 samples from kidney or liver transplant recipients were subjected to Dimension RxL HM with a tacrolimus Flex reagent cartilage for the ACMIA method and IMx tacrolimus II for the MEIA method. Results: Tacrolimus concentrations measured by the ACMIA method (n = 154) closely correlated with those measured by the MEIA method (r = 0.84). The Bland-Altman plot using concentration differences between the 2 methods and the average of the 2 methods showed no specific trends. The tacrolimus levels determined by both the MEIA method and the ACMIA method were not influenced by hematocrit levels, but the difference between the 2 methods (ACMIA - MEIA) tended to be larger in low hematocrit samples (P < .001). Conclusion: The ACMIA method used for a tacrolimus assay is precise and has advantages, including the lack of a required pretreatment procedure. Furthermore, it is only slightly influenced by the hematologic or biochemical status of the samples.

AB - Background: Tacrolimus is a potent immunosuppressive drug used in organ transplantation. Because of its substantial toxic effects, narrow therapeutic index, and interindividual pharmacokinetic variability, therapeutic drug monitoring of whole-blood tacrolimus concentrations has been recommended. We investigated the comparability of the results of 2 immunoassay systems, affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA), comparing differences in the tacrolimus concentrations measured by the 2 methods in relation to the hematologic and biochemical values of hepatic and renal functions. Methods: A total of 154 samples from kidney or liver transplant recipients were subjected to Dimension RxL HM with a tacrolimus Flex reagent cartilage for the ACMIA method and IMx tacrolimus II for the MEIA method. Results: Tacrolimus concentrations measured by the ACMIA method (n = 154) closely correlated with those measured by the MEIA method (r = 0.84). The Bland-Altman plot using concentration differences between the 2 methods and the average of the 2 methods showed no specific trends. The tacrolimus levels determined by both the MEIA method and the ACMIA method were not influenced by hematocrit levels, but the difference between the 2 methods (ACMIA - MEIA) tended to be larger in low hematocrit samples (P < .001). Conclusion: The ACMIA method used for a tacrolimus assay is precise and has advantages, including the lack of a required pretreatment procedure. Furthermore, it is only slightly influenced by the hematologic or biochemical status of the samples.

UR - http://www.scopus.com/inward/record.url?scp=57549088671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549088671&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2008.04.019

DO - 10.1016/j.transproceed.2008.04.019

M3 - Article

C2 - 19100463

AN - SCOPUS:57549088671

VL - 40

SP - 3673

EP - 3678

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -